Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the popular diabetes and obesity treatments , federal regulators said Friday.
The drugmaker Novo Nordisk can meet current and future demand in the U.S., the Food and Drug Administration said. But patients may still see some supply disruptions as the medications move from the manufacturer to distributors and then to pharmacies.
Watch 온라인카지노사이트 5 free wherever you are
WATCH HEREThe injectable drugs have been in shortage since 2022.
Compounding pharmacies and other entities that have been allowed to make and distribute off-brand copies of the drugs during the shortage will have to wind down production in the next few months, the FDA said.
Get top local stories delivered to you every morning with 온라인카지노사이트 DFW's News Headlines newsletter.
SIGN UP In December, the agency said the same thing when it declared that shortages had ended for Eli Lilly and Co.'s Zepbound and Mounjaro. Zepbound is approved to treat obesity and Mounjaro is approved for diabetes. They use the same active ingredient, tirzepatide.
Ozempic, for diabetes, and Wegovy, for weight loss, use the active ingredient semaglutide.
All four drugs are part of a GLP-1 class of treatments that has shown unprecedented results for helping people shed weight by decreasing appetite and boosting feelings of fullness.
Health Connection
Get connected to a healthier life.
Sales for the drugs in recent years. But the shortages and have made it difficult for many patients to get the drugs.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
